Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NYSE American - Delayed Quote USD

Impact BioMedical Inc. (IBO)

Compare
2.2800
+0.0800
+(3.64%)
At close: March 27 at 4:00:00 PM EDT
2.3300
+0.05
+(2.19%)
After hours: March 27 at 7:59:36 PM EDT
Loading Chart for IBO
  • Previous Close 2.2000
  • Open 2.5000
  • Bid --
  • Ask --
  • Day's Range 2.2305 - 2.6100
  • 52 Week Range 0.5080 - 6.1700
  • Volume 2,457,028
  • Avg. Volume 3,142,693
  • Market Cap (intraday) 26.229M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 22.80
  • EPS (TTM) 0.1000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.

www.impactbiomedinc.com

1

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IBO

View More

Performance Overview: IBO

Trailing total returns as of 3/27/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IBO
57.24%
S&P 500 (^GSPC)
3.20%

1-Year Return

IBO
24.00%
S&P 500 (^GSPC)
8.48%

3-Year Return

IBO
24.00%
S&P 500 (^GSPC)
25.32%

5-Year Return

IBO
24.00%
S&P 500 (^GSPC)
124.02%

Compare To: IBO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IBO

View More

Valuation Measures

Annual
As of 3/27/2025
  • Market Cap

    26.23M

  • Enterprise Value

    31.63M

  • Trailing P/E

    22.51

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.84

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    10.07

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -4.99%

  • Return on Equity (ttm)

    3.45%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    1.17M

  • Diluted EPS (ttm)

    0.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.67M

  • Total Debt/Equity (mrq)

    23.31%

  • Levered Free Cash Flow (ttm)

    -1.33M

Research Analysis: IBO

View More

Company Insights: IBO

Research Reports: IBO

View More

People Also Watch